New cocktail aims to shrink pancreatic tumors before surgery
NCT ID NCT05984602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding two immune-boosting drugs (canakinumab and tislelizumab) to standard chemotherapy can safely shrink pancreatic tumors before surgery. Nine adults with resectable or borderline resectable pancreatic cancer will receive the combination. The main goals are to find the best dose and see how many patients can then have successful surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ambulatory Care Center
New York, New York, 10016, United States
-
Clinical Cancer Center
New York, New York, 10016, United States
-
NYU Langone Ambulatory Care Center East 38th Street
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?